Feb 13 (Reuters) - ERYTECH PHARMA SA:
* ERYTECH SELECTS TRIPLE NEGATIVE BREAST CANCER AS NEXT INDICATION FOR ERYASPASE
* SET-UP ACTIVITIES FOR PHASE 2 CLINICAL STUDY ONGOING, PATIENT ENROLLMENT EXPECTED TO START Q3 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)